Author correction: <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> BLa80 for preventing allergic, respiratory, and gastrointestinal diseases in young children in China: a randomized double-blind placebo-controlled trial

Ke Chen; Xi Zhang; Kaihong Zeng; Jiayi Zhong; Shanshan Jin; Yang Nie; Ping Yang; Nianyang He; Haixia Chen; Yanmei Cao; Yunrong Fu; Ziji Fang; Wei Jiang; Changqi Lium

doi:10.3345/cep.2026.err01

Erratum: Authour correciton

Author correction: Bifidobacterium animalis subsp. lactis BLa80 for preventing allergic, respiratory, and gastrointestinal diseases in young children in China: a randomized double-blind placebo-controlled trial

Ke Chen, PhD^1,^*, Xi Zhang, MD^1,^*, Kaihong Zeng, PhD^2,^*, Jiayi Zhong, MD¹, Shanshan Jin, MD¹, Yang Nie, BD³, Ping Yang, BD⁴, Nianyang He, BD⁴, Haixia Chen, BD⁵, Yanmei Cao, BD⁶, Yunrong Fu, BD⁷, Ziji Fang, MD⁸, Wei Jiang, PhD⁹, Changqi Lium, PhD¹⁰

¹Department of Clinical Nutrition, Chengdu Women’s & Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

²Department of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China

³Department of Child Health Care, Chongzhou Maternal and Child Health Care Hospital, Chengdu, China

⁴Department of Child Health Care, Xindu Maternal and Child Health Care Hospital, Chengdu, China

⁵Baoxing Central for Disease Prevention and Control, Sichuan, China

⁶Department of Child Health Care, Dayi Maternal and Child Health Care Hospital, Sichuan, China

⁷Department of Child Health Care, Jinniu Maternal and Child Health Care Hospital, Sichuan, China

⁸School of Medicine, University of Electronic Science and Technology of China, Sichuan, China

⁹Laboratory of Microbiology, Immunology and Metabolism, Diprobio (Shanghai) Co., Limited, Shanghai, China

¹⁰School of Exercise and Nutritional Sciences, San Diego State University, San Diego, CA, USA

^* These authors contributed equally to this study as co-first authors.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Clinical and Experimental Pediatrics 2026;69(5):455.

Published online: April 28, 2026

DOI: https://doi.org/10.3345/cep.2026.err01

This corrects the article "Bifidobacterium animalis subsp. lactis BLa80 for preventing allergic, respiratory, and gastrointestinal diseases in young children in China: a randomized double-blind placebo-controlled trial" via https://doi.org/10.3345/cep.2025.01256.

Clinical and Experimental Pediatrics 2026;69(2):150-162.

Published online: October 30, 2025

https://doi.org/10.3345/cep.2025.01256

To the editor,

Upon careful re-examination of the published article, we identified two inadvertent errors in the Results section of the Abstract. The original text incorrectly stated the direction of change for antimicrobial peptide levels between the intervention group (IG) and control group (CG).

We sincerely apologize for this editorial oversight. This correction does not alter the primary conclusions of the study regarding the efficacy of Bifidobacterium animalis subsp. lactis BLa80 in preventing allergic, respiratory, and gastrointestinal diseases in young children.

The two errors should be corrected as follows:

1. First correction

Original (incorrect): "Postintervention, the IG had significantly lower concentrations of LL-37 ..."

Corrected: "Postintervention, the IG had significantly higher concentrations of LL-37..."

2. Second correction

Original (incorrect): “Probiotic supplementation was also associated with a lower risk of URTIs (IG vs. CG: 40.3% vs. 20.7%; risk ratio [RR], 0.752; 95% confidence interval [CI], 0.653–0.866)…”

Corrected: “Probiotic supplementation was also associated with a lower risk of URTIs (CG vs. IG: 40.3% vs. 20.7%; risk ratio [RR], 0.752; 95% confidence interval [CI], 0.653–0.866)...”